The D355A mutant, which has increased capping efficiency and viral gene expression, was found to be significantly more resistant to type I IFN treatment early during infection than wild-type SINV, with the viral titer being reduced by only ∼1 log when IFN was added at 0 hpi (Fig. 5B). The gene discussed is IFNA1; the disease is infection.